Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

StrategyPain ManagementOTCSafety Signal

Omega Pharma recalls Napralief 250mg Tablets due to PIL deficiencies

The recall of Napralief 250mg due to deficiencies in the Patient Information Leaflet poses a risk to Omega Pharma's market position and consumer trust. Competitors may capitalize on this situation, necessitating a proactive response from portfolio teams to mitigate potential impacts.

Published: June 29, 2026
Updated: June 29, 2026
Author: Humanexa Intelligence
Therapeutic area: Pain Management / OTC
Company: Omega Pharma Ltd
Asset: Omega
Score8.2

Signal

Omega Pharma recalls Napralief 250mg Tablets due to PIL deficiencies

Company

Omega Pharma Ltd

Category

Strategy

Therapeutic Area

Pain Management / OTC

Action

Monitor

Signal assessment

Signal strength

high

Confidence level

moderate

Signalhigh
Confidencemoderate

Strategic implication

The recall of Napralief 250mg due to deficiencies in the Patient Information Leaflet poses a risk to Omega Pharma's market position and consumer trust. Competitors may capitalize on this situation, necessitating a proactive response from portfolio teams to mitigate potential impacts.

Why it matters

The recall of Napralief 250mg due to deficiencies in the Patient Information Leaflet poses a risk to Omega Pharma's market position and consumer trust. Competitors may capitalize on this situation, necessitating a proactive response from portfolio teams to mitigate potential impacts.

What changed

Safety Signal

Analysis

Omega Pharma Ltd is recalling specific batches of Napralief 250mg Gastro-Resistant Tablets due to missing information in the Patient Information Leaflet.

The recall of Napralief 250mg due to deficiencies in the Patient Information Leaflet poses a risk to Omega Pharma's market position and consumer trust. Competitors may capitalize on this situation, necessitating a proactive response from portfolio teams to mitigate potential impacts.

Monitor for updates on the recall process and any potential regulatory actions or consumer reactions.

Related companies & assets

Companies

  • Omega Pharma Ltd →

Assets

  • Omega →

Sources & Humanexa intelligence

Source links

  • Omega Pharma recalls Napralief 250mg Tablets due to PIL deficiencies ↗

Related Humanexa pages

  • Omega Pharma recalls Napralief 250mg Tablets due to PIL deficiencies →

Related signals

Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval

Company

Micro Labs

Asset

FDA

Indication

Psychiatry / Antidepressant

Status

Approved

Signal Score

8.2

Strategyhigh signal

FDA Approves ANDA for Escitalopram Oxalate by Micro Labs

The FDA has granted approval for ANDA091655, a generic version of Escitalopram Oxalate submitted by Micro Labs.

July 5, 2026Read signal →
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval

Asset

Shuangcheng

Indication

Gastroenterology / Proton Pump Inhibitor

Status

Approved

Signal Score

8.2

Strategyhigh signal

FDA Grants Approval for Pantoprazole Sodium ANDA219973

The FDA has granted approval for ANDA219973, a generic version of Pantoprazole Sodium, submitted by Shuangcheng.

July 5, 2026Read signal →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.